H.R. 8857 aims to modify the criteria for which engineered cyclic peptides can be classified as qualifying single source drugs under the Drug Price Negotiation Program. This adjustment may affect how these drugs are priced and negotiated in the context of Medicare and Medicaid.
Supporters of H.R. 8857 argue that the bill will enhance access to innovative therapies by ensuring that more engineered cyclic peptides are eligible for price negotiations, potentially lowering costs for patients and taxpayers.
Critics of H.R. 8857 express concerns that the changes could complicate the Drug Price Negotiation Program and may lead to unintended consequences, such as reduced investment in drug development or increased prices for certain medications.
The bill H.R. 8857, which aims to amend the Social Security Act regarding engineered cyclic peptides, presents a significant potential conflict of interest for its sponsor, Joseph Morelle. His top donor industry, Health Professionals, contributed a staggering $120 million, which directly overlaps with the bill's subject matter concerning drug pricing and negotiation. This substantial financial backing raises questions about whether the interests of these donors could influence the legislative process in favor of the pharmaceutical sector, particularly in terms of pricing and accessibility of single-source drugs.
Moreover, the lobbying activity surrounding this bill further complicates the landscape. Various entities, including CURIO with a disclosed $10,000 and several others with undisclosed amounts, are involved in lobbying efforts that could align with the interests of the health professionals who are significant donors to Morelle. This creates a scenario where the financial interests of the health industry may unduly influence legislative outcomes, potentially prioritizing profit over public health. Voters should be aware of these connections as they may impact the integrity of drug pricing negotiations.
These industries are both affected by this bill and among the sponsor's top donors.
| Industry | Match Type | Related Subject | Donations |
|---|---|---|---|
| Health Professionals (H01) | Sector | Health | $120,000,000 |
| Total from overlapping industries | $120,000,000 | ||
Organizations that lobbied on issues related to this bill's policy area.
| Client | Lobbying Firm | Amount |
|---|---|---|
| SYNGENTA CORPORATION | CHECKMATE GOVERNMENT RELATIONS | $140,000 |
| NATIONAL COUNCIL OF NONPROFITS (FORMERLY KNOWN AS THE NATIONAL COUNCIL OF NONPRO | NATIONAL COUNCIL OF NONPROFITS (FORMERLY KNOWN AS THE NATIONAL COUNCIL OF NONPRO | $85,660 |
| COUNTY OF LOS ANGELES | TORRES CONSULTING, LLC | $20,000 |
| CURIO | CURIO | $10,000 |
| WILLOW LABORATORIES | WILLOW LABORATORIES | undisclosed |
| ECONOINVEST HOLDING LLC | CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS | undisclosed |
| FIELD TECH INTERNATIONAL CORP | CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS | undisclosed |
| SYNCHRON, INC. | KING & SPALDING LLP | undisclosed |
| GIFT-IN-KIND MARKETPLACE | MICHAEL BEST STRATEGIES LLC | undisclosed |
| BROADBAND CONNECT | B ARCHETYPE | undisclosed |
| STELLAR DEVELOPMENT FOUNDATION | STELLAR DEVELOPMENT FOUNDATION | undisclosed |
| FONTAINEBLEAU DEVELOPMENT | CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS | undisclosed |
| CITY OF EL PASO | FORWARD GLOBAL | undisclosed |
| FOREST RIVER BUS, LLC | CFM STRATEGIC COMMUNICATIONS (CONKLING FISKUM & MCCORMICK) | undisclosed |
| INTERNATIONAL MINERALS CARLSBAD, LLC | VALIANT STRATEGIES LLC | undisclosed |
Source: Senate Lobbying Disclosure Act (LDA) filings, 2026
Top industries funding Joseph Morelle, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
